0855 ET - Stifel says CoreWeave's acquisition of Core Scientific could bolster CoreWeave's ability to scale, free up around $10 billion in lease liability commitments and about $5 billion in committed capex, among other benefits, but the analysts remain cautious short-term. "While we are positive on the longer-term benefits from the acquisition, we think there are key near-term overhangs for CoreWeave to pass," say the analysts, who downgrade CoreWeave to hold but raise the price target to $115 from $75. CoreWeave is down 1.3% premarket. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
July 08, 2025 08:55 ET (12:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.